HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Sales Soar, But Firm Confronts Renewed Scrutiny

This article was originally published in The Tan Sheet

Executive Summary

CEO William Johnson says the firm had “another record performance of double-digit growth while under the constant and unrelenting attack” by activist investor William Ackman. Herbalife executives have met with Sen. Edward Markey’s staff and say they have answered the questions he asked in a January letter.

You may also be interested in...



Herbalife Pushes To Counter Pyramid Scheme Narrative

The multilevel marketer of weight-management shakes and other nutritionals says its independent distributor network, far from being a pyramid scheme, in fact is essential in helping people lose weight and adopt healthy lifestyles, according to Herbalife executives.

Bayer Relates Feeling ‘Sexy’ To Quick Relief For Allergies In Astepro Allergy Ad Campaign

Campaign featuring actress Meghann Fahy says "allergy sufferers can relieve their allergy symptoms and be more spontaneous in their romantic pursuits.” Ads launch two months after FDA granted tentative approval for two ANDAs for generic equivalents, indicating approval could come pending resolution of patent litigation.

US Infant Formula Supply Chain Strategy Delivered

FDA immediate actions include ensuring providers know they’re required to develop redundancy risk management plans, enhancing inspections of manufacturers, including by expanding and improving training for investigators, and expediting reviews of premarket submissions for new products.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel